YDES

YD Bio Ltd

6.20

Nov 02 • 1:48 PM ET +0.26 (4.38%)

Healthcare Biotechnology Taiwan Small NASD

Peers: SLBT MENS ANIX ALDX OKYO CDIO HIND ALPS ABVC IGC

Index	-
Market Cap	439.23M
Enterprise Value	436.58M
Income	-
Sales	-
Book/sh	0.06
Cash/sh	0.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Dec 23, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	98.18
P/C	165.12
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.46
Current Ratio	5.23
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- 6.41%
Sales past 3/5Y	- -
EPS Y/Y TTM	14.61%
Sales Y/Y TTM	-
EPS Q/Q	-116.03%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	80.12%
Insider Trans	0.06%
Inst Own	0.40%
Inst Trans	11.40%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.61%
SMA50	20.30%
SMA200	12.79%
Trades

Shs Outstand	70.84M
Shs Float	14.09M
Short Float	1.36%
Short Ratio	0.64
Short Interest	0.19M
52W High	15.72 -60.56%
52W Low	1.70 264.71%
Volatility	12.73% 17.81%
ATR (14)	0.88
RSI (14)	54.30
Beta	-0.60
Rel Volume	0.16
Avg Volume	299.82K
Volume	32,971

Perf Week	17.20%
Perf Month	-23.55%
Perf Quarter	167.24%
Perf Half Y	23.50%
Perf YTD	-49.14%
Perf Year	-45.76%
Perf 3Y	-44.39%
Perf 5Y	-39.04%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	5.94
Price	6.20
Change %	4.38%

Oct-20-26 08:00AM	YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs (GlobeNewswire)
Oct-06-26 08:00AM	YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment (GlobeNewswire) -13.50%
Aug-31-26 06:00PM	YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 (GlobeNewswire) -22.71%
Aug-25-26 08:00AM	YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute (GlobeNewswire)
Aug-11-26 08:00AM	YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute (GlobeNewswire) +8.98%
08:00AM	Loading…
Aug-04-26 08:00AM	YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research (GlobeNewswire)
Jul-28-26 08:00AM	YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada (GlobeNewswire)
Jul-23-26 08:00AM	YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services (GlobeNewswire) -7.69%
Jul-02-26 08:00AM	YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations (GlobeNewswire) -17.75%
Apr-30-26 06:00PM	YD Bio Limited Reports Full Year 2025 Financial Results (GlobeNewswire) -5.88%
Mar-31-26 08:00AM	YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States (GlobeNewswire)
Mar-17-26 08:00AM	YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem (GlobeNewswire) -8.55%
Feb-25-26 08:00AM	YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform (GlobeNewswire)
Jan-29-26 08:30AM	YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy (GlobeNewswire) -9.89%
Jan-06-26 09:00AM	YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development (GlobeNewswire) -8.04%
09:00AM	Loading…
Jan-05-26 09:00AM	YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap (GlobeNewswire) +5.67%
Dec-16-25 09:00AM	YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center (GlobeNewswire)
Dec-09-25 09:00AM	YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN (GlobeNewswire) -18.42%
Dec-02-25 09:00AM	YD Bio Limited Expands OkaiDx Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection (GlobeNewswire)
Nov-24-25 09:00AM	YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics (GlobeNewswire)
Nov-05-25 08:30AM	YD Bio and EG BioMed Expand U.S. Access to OkaiDx, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring (GlobeNewswire)
Oct-20-25 10:20AM	YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES (GlobeNewswire)
Oct-10-25 08:37AM	YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities (GlobeNewswire) -6.95%
Aug-29-25 07:30AM	YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market (PR Newswire) +135.85%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shen Ethan PhD	CEO	Sep 14 '26	Buy	3.85	12,700	48,895	11,258,331	Sep 16 04:01 PM
Shen Ethan PhD	CEO	Sep 09 '26	Buy	3.93	3,100	12,183	11,245,631	Sep 10 04:01 PM
Shen Ethan PhD	CEO	Sep 04 '26	Buy	3.67	18,378	67,447	11,242,531	Sep 08 04:00 PM

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation-based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company's offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

CEO & ChairmanDr. Ethan Shen Ph.D.

F.C.A.Mr. Edmund Hen C.P.A.

Chief Medical Officer & DirectorDr. Benjamin Zhang M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

YDES

YD Bio Ltd

Upgrade your Finviz experience